1167056-89-4 Usage
Description
6-Fluoro-3-hydroxy-quinoline-4-carboxylic acid, commonly known as flumequine, is a synthetic broad-spectrum antibiotic that belongs to the fluoroquinolone class. It is characterized by its ability to inhibit bacterial DNA gyrase, which disrupts DNA replication and leads to the death of bacteria. Flumequine is effective against a wide range of gram-positive and gram-negative bacteria, making it a valuable tool in veterinary medicine.
Uses
Used in Veterinary Medicine:
6-Fluoro-3-hydroxy-quinoline-4-carboxylic acid is used as a broad-spectrum antibiotic for treating various bacterial infections in animals. Its effectiveness against a wide range of bacteria makes it a valuable tool in this industry.
Used in Environmental Management:
6-Fluoro-3-hydroxy-quinoline-4-carboxylic acid is used as an environmental contaminant monitor for assessing the impact of antibiotic residues in water bodies. Its presence in water has been linked to adverse effects on aquatic organisms, highlighting the need for careful use and disposal to minimize potential harm to the environment and human health.
Used in Food Safety Regulation:
6-Fluoro-3-hydroxy-quinoline-4-carboxylic acid is used as a marker for monitoring antibiotic residues in meat products from food-producing animals. Concerns about potential antibiotic resistance and residues in these products have led to the need for strict regulation and management of flumequine use in the food industry.
Check Digit Verification of cas no
The CAS Registry Mumber 1167056-89-4 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,6,7,0,5 and 6 respectively; the second part has 2 digits, 8 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 1167056-89:
(9*1)+(8*1)+(7*6)+(6*7)+(5*0)+(4*5)+(3*6)+(2*8)+(1*9)=164
164 % 10 = 4
So 1167056-89-4 is a valid CAS Registry Number.
1167056-89-4Relevant articles and documents
PF-07059013: A Noncovalent Modulator of Hemoglobin for Treatment of Sickle Cell Disease
Gopalsamy, Ariamala,Aulabaugh, Ann E.,Barakat, Amey,Beaumont, Kevin C.,Cabral, Shawn,Canterbury, Daniel P.,Casimiro-Garcia, Agustin,Chang, Jeanne S.,Chen, Ming Z.,Choi, Chulho,Dow, Robert L.,Fadeyi, Olugbeminiyi O.,Feng, Xidong,France, Scott P.,Howard, Roger M.,Janz, Jay M.,Jasti, Jayasankar,Jasuja, Reema,Jones, Lyn H.,King-Ahmad, Amanda,Knee, Kelly M.,Kohrt, Jeffrey T.,Limberakis, Chris,Liras, Spiros,Martinez, Carlos A.,McClure, Kim F.,Narayanan, Arjun,Narula, Jatin,Novak, Jonathan J.,O'Connell, Thomas N.,Parikh, Mihir D.,Piotrowski, David W.,Plotnikova, Olga,Robinson, Ralph P.,Sahasrabudhe, Parag V.,Sharma, Raman,Thuma, Benjamin A.,Vasa, Dipy,Wei, Liuqing,Wenzel, A. Zane,Withka, Jane M.,Xiao, Jun,Yayla, Hatice G.
, p. 326 - 342 (2021/01/14)
Sickle cell disease (SCD) is a genetic disorder caused by a single point mutation (β6 Glu → Val) on the β-chain of adult hemoglobin (HbA) that results in sickled hemoglobin (HbS). In the deoxygenated state, polymerization of HbS leads to sickling of red blood cells (RBC). Several downstream consequences of polymerization and RBC sickling include vaso-occlusion, hemolytic anemia, and stroke. We report the design of a noncovalent modulator of HbS, clinical candidate PF-07059013 (23). The seminal hit molecule was discovered by virtual screening and confirmed through a series of biochemical and biophysical studies. After a significant optimization effort, we arrived at 23, a compound that specifically binds to Hb with nanomolar affinity and displays strong partitioning into RBCs. In a 2-week multiple dose study using Townes SCD mice, 23 showed a 37.8% (±9.0%) reduction in sickling compared to vehicle treated mice. 23 (PF-07059013) has advanced to phase 1 clinical trials.
